| Investigating the Effects of Hydroxyvitamin D3 on Multiple Sclerosis (NCT05340985) | Tehran University of Medical Sciences | 2022-07-01 |
| PENTAGON: MS-Related Disability Worsening and Thalamic Volume Loss (NCT07753928) | Jung Diagnostics GmbH | 2022-07-01 |
| Effect of Computerized Cognitive Training in Persons With MS (NCT05345288) | University of Nebraska | 2022-06-28 |
| Exercise Effects in Multiple Sclerosis (NCT05496881) | University of Regina | 2022-06-15 |
| Multiparametric Assessment to Investigate Prognostic Factors for Disease Evolution a nd Evolutionary Patterns of Cognitive Status in RRMS (NCT05510817) | University Hospital of Mont-Godinne | 2022-06-06 |
| A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis (NCT05265728) | Biogen | 2022-04-26 |
| B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis (NCT05296161) | Amsterdam UMC, location VUmc | 2022-04-20 |
| Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis (NCT05168384) | Abu Dhabi Stem Cells Center | 2022-03-26 |
| Efficacy of Diet on Quality of Life in Multiple Sclerosis (NCT05007483) | Terry L. Wahls | 2022-02-10 |
| Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis (NCT05201638) | Immunic AG | 2022-01-12 |
| MS-ResearchBiomarkerS (NCT05204459) | Cedars-Sinai Medical Center | 2021-11-11 |
| Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy (NCT05028634) | Celgene | 2021-11-11 |
| A Post-Authorization, Long-term Study of Ozanimod Real-world Safety (NCT05605782) | Bristol-Myers Squibb | 2021-09-02 |
| Corticosteroid Effects on Asymptomatic Gadolinium-enhancing Lesions in Multiple Sclerosis (NCT04979650) | Mazandaran University of Medical Sciences | 2021-05-22 |
| Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI (NCT04448977) | Kessler Foundation | 2021-05-06 |
| Hematopoietic Stem Cell Transplantation for Treatment of Multiple Sclerosis in Sweden (NCT05029206) | Uppsala University | 2021-05-05 |
| Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program (NCT04655222) | Biogen | 2021-04-30 |
| Effects of Oral Cladribine on Remyelination and Inflammation in Multiple Sclerosis Patients (NCT05902429) | Pontificia Universidade Católica do Rio Grande do Sul | 2021-04-28 |
| Examining Effects of Tysabri on Cognitive Fatigue Using fMRI (NCT04565431) | Kessler Foundation | 2021-03-19 |
| Real World Analysis on Lymphocyte Reconstitution After Lymphopenia in Participants Treated by Tecfidera (NCT04756687) | Biogen | 2021-03-10 |
| A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia®) (NCT05335031) | Bristol-Myers Squibb | 2021-03-03 |
| Evaluation of Relapse Presence in Multiple Sclerosis (NCT05218317) | Marmara University | 2021-01-01 |
| Evaluation of the Impact of Lesions of the Motor and Proprioceptive Brain and Pan-medullary Pathways on Their Clinically and Electrophysiologically Assessed Function in Multiple Sclerosis (NCT04220814) | Rennes University Hospital | 2020-11-03 |
| Speech in Noise Discrimination Skills in Multiple Sclerosis Patients. (NCT06381297) | Asuman Kucukoner | 2020-10-09 |
| Feasibility Study of Tolerogenic Fibroblasts in Patients With Refractory Multiple Sclerosis (NCT05080270) | FibroBiologics | 2020-09-21 |
| Effect of CoDuSe Balance Training and Step Square Exercises on Risk of Fall in Multiple Sclerosis (NCT04528121) | Lama Saad El-Din Mahmoud | 2020-09-15 |
| Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort (NCT04580381) | University Hospital, Caen | 2020-09-01 |
| Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine (NCT05019248) | Heinrich-Heine University, Duesseldorf | 2020-09-01 |
| Wireless, Implantable Tibial Nerve Stimulator System for the Treatment of Refractory Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis (NCT04567264) | Chiara Zecca | 2020-08-26 |
| Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis (NCT04261790) | Johns Hopkins University | 2020-08-01 |
| Calorie Restriction in Multiple Sclerosis (NCT04042415) | Federico II University | 2020-07-14 |
| Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS). (NCT04260711) | Amsterdam UMC, location VUmc | 2020-07-01 |
| The Effects of Relaxation Techniques on Pain, Fatigue and Kinesiophobia in Multiple Sclerosis Patients: A Three Arms Randomized Trial (NCT04833673) | Hacettepe University | 2020-06-22 |
| Delayed Diagnosis of Multiple Sclerosis, Treatment Initiation and Non-adherence in Upper Egypt (NCT05438693) | doaa mokhtar mahmoud | 2020-06-01 |
| Development and Evaluation of a Web-based Programme on Relapse Management for People With Multiple Sclerosis (NCT04233970) | Universitätsklinikum Hamburg-Eppendorf | 2020-02-17 |
| Phase II Clinical Trial of OCH-NCNP1 (NCT04211740) | National Center of Neurology and Psychiatry, Japan | 2019-12-06 |
| tDCS to Enhance Cognitive Training in Multiple Sclerosis (NCT04261556) | University of Milano Bicocca | 2019-11-21 |
| TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis (NCT03910738) | University Hospital, Strasbourg, France | 2019-10-29 |
| Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis (NCT03963375) | Gregory Wu | 2019-10-28 |
| PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes. (NCT03942952) | University of Texas Southwestern Medical Center | 2019-10-22 |
| To Investigate the Effect of Aerobic Exercise on Neurophysiological Values and Functionality in Individuals With Multiple Sclerosis. (NCT04121637) | Firat University | 2019-10-21 |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis (NCT03958877) | Biogen | 2019-10-18 |
| A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS (NCT04121221) | Mapi Pharma Ltd. | 2019-09-19 |
| Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis (NCT04002934) | Riley Bove, MD | 2019-09-10 |
| Exploration of Brain Changes Due to a Targeted Ballet Program in Multiple Sclerosis (NCT04073940) | University of Illinois at Urbana-Champaign | 2019-08-29 |
| A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab (NCT04048577) | Berkovich, Regina MD, PhD Inc. | 2019-07-03 |
| Cognition and MRI Markers in MS Patients With Aubagio® Treatment (NCT03768648) | University Hospital, Bordeaux | 2019-05-21 |
| Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants (NCT03870763) | Biogen | 2019-03-19 |
| Understanding Magnetic Resonance Imaging in Multiple Sclerosis (NCT03872583) | Universitätsklinikum Hamburg-Eppendorf | 2019-03-15 |
| Sensitivity of Motor Assessment in MS - a Prospective Cohort Study (NCT04993274) | Friedemann Paul | 2019-02-20 |
| A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration (NCT03689972) | Biogen | 2018-11-27 |
| The Reliability, Validity, and Responsiveness of the Timed 360° Turn Test in Patients With Multiple Sclerosis (NCT03718026) | Gazi University | 2018-10-24 |
| Fecal Microbiota Transplantation (FMT) in Multiple Sclerosis (NCT03975413) | Rush University Medical Center | 2018-09-25 |
| Cortical Lesions in Patients With Multiple Sclerosis (NCT03653585) | Danish Research Centre for Magnetic Resonance | 2018-09-04 |
| Immunoadsorption Versus High-dose Intravenous Corticosteroids in Relapsing Multiple Sclerosis (NCT04450030) | University Hospital Muenster | 2018-08-01 |
| RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS (NCT03979456) | Karolinska Institutet | 2018-07-04 |
| Acute Intermittent Hypoxia in Persons With Multiple Sclerosis (NCT04280484) | Shirley Ryan AbilityLab | 2018-06-18 |
| Longitudinal Effect of Vitamin D3 Replacement on Cognitive Performance and MRI Markers in Multiple Sclerosis Patients (NCT03610139) | American University of Beirut Medical Center | 2018-05-21 |
| Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (NCT03500328) | Johns Hopkins University | 2018-05-02 |
| Photobiomodulation Therapy in Persons With Multiple Sclerosis (NCT03691766) | Marquette University | 2018-04-30 |
| A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS) (NCT03387046) | Merck KGaA, Darmstadt, Germany | 2018-03-26 |
| Retinal Neuro-vascular Coupling in Patients With Multiple Sclerosis (NCT03401879) | Medical University of Vienna | 2018-02-01 |
| Impact of Vitamin D Supplementation in Patients With Multiple Sclerosis (NCT03385356) | University Medical Centre Maribor | 2017-12-19 |
| A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis (NCT03347370) | Biogen | 2017-11-27 |
| Maximizing Outcome of Multiple Sclerosis Transplantation (NCT03342638) | Northwestern University | 2017-11-08 |
| Clinical Decision Support System (CADIMS) for MS Diagnostic (NCT03205280) | Rennes University Hospital | 2017-10-11 |
| Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis (NCT02744222) | Biocad | 2017-08-10 |
| Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS) (NCT02903537) | Fundació Institut Germans Trias i Pujol | 2017-07-06 |
| A Study for Tecfidera (Dimethyl Fumarate) Capsules in Korean Participants With Relapsing-Remitting Multiple Sclerosis (NCT05366036) | Eisai Korea Inc. | 2017-06-14 |
| Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple Sclerosis (NCT03239860) | GeNeuro SA | 2017-06-06 |
| Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate (NCT02901106) | Fondation Ophtalmologique Adolphe de Rothschild | 2017-05-23 |
| Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS) (NCT03126760) | Mallinckrodt ARD LLC | 2017-05-22 |
| Light Therapy as Treatment for Fatigue in Multiple Sclerosis (NCT03060759) | Massachusetts General Hospital | 2017-04-01 |
| Effects of Task-oriented Training on Functional Mobility and Fatigue in Patients With Multiple Sclerosis (NCT03497468) | Bezmialem Vakif University | 2017-01-01 |
| Biomarkers and Disease Activity in Patients Treated With Teriflunomide (Aubagio) (NCT03561402) | McGill University | 2016-12-01 |
| A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) (NCT02861014) | Hoffmann-La Roche | 2016-09-09 |
| Dietary Approaches to Treat Multiple Sclerosis-Related Fatigue Study (NCT02914964) | Terry L. Wahls | 2016-08-01 |
| Effects Aquatic Exercises on Balance and Hand Function in Multiple Sclerosis (NCT03679806) | Dokuz Eylul University | 2016-05-01 |
| Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS (NCT02675413) | Washington University School of Medicine | 2016-04-01 |
| Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS (NCT02782858) | GeNeuro SA | 2016-04-01 |
| Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) (NCT02555215) | Biogen | 2016-02-22 |
| A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) (NCT02637856) | Genentech, Inc. | 2016-02-11 |
| Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction (NCT02652091) | Bayer | 2016-02-05 |
| Participants Preferences to Disease Modifying Agents in Relapsing Remitting Multiple Sclerosis Condition (NCT02598167) | Hoffmann-La Roche | 2015-12-07 |
| Observational Registry of Acthar Gel for Participants With Multiple Sclerosis Relapse (NCT02633033) | Mallinckrodt | 2015-11-24 |
| Tecfidera and the Gut Microbiota (NCT02471560) | Biogen | 2015-11-06 |
| A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis (NCT02545868) | Hoffmann-La Roche | 2015-10-27 |
| Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS (NCT02410200) | Biogen | 2015-09-30 |
| Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS). (NCT02525874) | Biogen | 2015-08-11 |
| Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis (RRMS) (NCT02493049) | University of Calgary | 2015-08-01 |
| Open-label Study of Liothyronine in MS (NCT02506751) | Johns Hopkins University | 2015-07-01 |
| ACTH for Fatigue in Multiple Sclerosis Patients (NCT02315872) | Providence Health & Services | 2015-05-22 |
| Oral Guanabenz for Multiple Sclerosis (NCT02423083) | National Institute of Neurological Disorders and Stroke (NINDS) | 2015-04-21 |
| A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS (NCT02587806) | Novo Cellular Medicine Institute LLP | 2015-02-01 |
| This is a Randomized Study Comparing Two Doses of INT131 ( 3 mg and 1 mg) Administered Orally (PO) Daily (QD) Versus Placebo 1 Tablet PO QD in Subjects With Treatment-naïve RRMS for ≤ 3 Years (NCT02638038) | InteKrin Therapeutics, Inc. | 2015-02-01 |
| Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL) (NCT02394782) | Merck KGaA, Darmstadt, Germany | 2015-02-01 |
| Rotating Frame Relaxation Imaging in Patients With Multiple Sclerosis (NCT02403570) | Turku University Hospital | 2015-02-01 |
| A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS (NCT02587715) | Novo Cellular Medicine Institute LLP | 2015-02-01 |
| A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS (NCT02418325) | Genesis Limited | 2015-02-01 |
| A Trial for Evaluating Both Safety and Preliminary Efficacy of a Single Infusion of Stimulated Autologous CD4+T Cells in Patients With Relapsing- Remitting Multiple Sclerosis (NCT02427776) | Imcyse SA | 2015-01-01 |